Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Publication Type:

Journal Article


Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 52, Issue 6, p.896-900 (2011)


2011, Adult, Aged, Antibodies, Monoclonal, Antigens, CD20, Antineoplastic Agents, Bone Marrow, Bone Marrow Diseases, Clinical Research Division, Drug Resistance, Neoplasm, England, Europe, Female, Follow-Up Studies, Humans, Interferon Type I, Recombinant, Lymphoma, Non-Hodgkin, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Radioimmunotherapy, Radiometry, Radiopharmaceuticals, Remission Induction, Switzerland, United States


The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma.